'Cause mortality' diaporamas de présentation

A Senior Moment

1.56k views • 98 slides

The Old Paradigm (The full cup)

1.08k views • 76 slides

Observational Studies

799 views • 57 slides

HRV and Risk Stratification: Post-MI

HRV and Risk Stratification: Post-MI. Phyllis K. Stein, Ph.D. Washington University School of Medicine St. Louis, MO. Outline. Research vs. clinical Holter scanning. Caveats in interpretation of published studies. HRV predictors of mortality post-MI.

640 views • 37 slides

STANDARDIZED RATES AND RATIOS

STANDARDIZED RATES AND RATIOS. Nigel Paneth. MORTALITY RATES. (mortality rates are usually incidence rates, and therefore need a time dimension). 1. (All-cause or crude) mortality rate = total deaths in a year Estimate of people alive during that year*

1.03k views • 34 slides

Childhood Obesity is the Ultimate Health Disparity

340 views • 23 slides

The IDF Diabetes Atlas 5 th Edition

The IDF Diabetes Atlas 5 th Edition. A summary of the figures and key findings. Acknowledgements.

1.29k views • 23 slides

Background

Background. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, raises HDL-C levels, but the functional effects of these increases remain uncertain.

442 views • 21 slides

Fish oil

625 views • 20 slides

Some issues affecting Britain today

Some issues affecting Britain today. Part I Health Problems in Britain Part II Traffic in Britain Part III Countryside Conflicts. HEALTHY CITY PROJECT. In 1997 Stoke launched the Healthy City Project as part of the World Health Organisation Healthier City Network aiming to

324 views • 19 slides

The Impact of Revascularization on Mortality in Patients with Non-Acute Coronary Artery Disease

The Impact of Revascularization on Mortality in Patients with Non-Acute Coronary Artery Disease. Allen Jeremias MD MSc, Sanjay Kaul MD, Luis Gruberg MD, Todd K. Rosengart MD, David L. Brown MD Divisions of Cardiovascular Medicine and Cardiothoracic Surgery

372 views • 17 slides

When Using DOPPS Slides

When Using DOPPS Slides. DOPPS Slide Use Guidelines. Correlates and Outcomes of Dementia among Dialysis Patients: the Dialysis Outcomes and Practice Patterns Study . Introduction . DOPPS Background . Methods (1). Methods (2).

454 views • 16 slides

Lancet 2000;355:1582-87

Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival Study ELITE II.

558 views • 12 slides

Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support

SURVIVE-W. Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support. Presented at The American Heart Association Scientific Sessions, November 2005 Presented by Dr. Alexandre Mebazaa. SURVIVE-W: Background.

477 views • 8 slides

1.49k views • 7 slides

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002;288:2981-2997. ALLHAT. 42,418 patients with hypertension SBP > 140mmHg and/or DBP > 90 mmHg OR Took medication for hypertension and had at least one additional risk factor for CHD

263 views • 7 slides

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002;288:2981-2997. ALLHAT. 42,418 patients with hypertension SBP > 140mmHg and/or DBP > 90 mmHg OR Took medication for hypertension and had at least one additional risk factor for CHD

407 views • 7 slides

Valsartan in Acute Myocardial Infarction Trial Investigators

VALIANT Trial. Valsartan in Acute Myocardial Infarction Trial Investigators . Presented at American Heart Association Scientific Sessions 2003 Marc A. Pfeffer, et al. N Engl J Med 2003;349:1893-906. VALIANT Trial.

627 views • 5 slides

Sudden Cardiac Death in Heart Failure Trial

SCD-HeFT. Sudden Cardiac Death in Heart Failure Trial. Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy. SCD-HeFT. 2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ?35% Randomized, double-blind, multicenter.

394 views • 4 slides

ASCOT-LLA Extension Study

ASCOT-LLA Extension Study. Objective 11-year mortality follow-up of the lipid-lowering arm of ASCOT in the UK Background

627 views • 3 slides